Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
About this trial
This is an interventional treatment trial for Bladder Cancer focused on measuring stage III bladder cancer, regional transitional cell cancer of the renal pelvis and ureter, anterior urethral cancer, posterior urethral cancer, urethral cancer associated with invasive bladder cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed carcinoma of the urothelium, meeting 1 of the following criteria for locally advanced disease: Clinical stage T3b disease, defined by presence of a mass on examination under anesthesia Clinical stage T4a disease, defined by direct invasion of prostatic stroma, vagina, or rectum Lymphovascular invasion on transurethral resection specimen Upper tract disease or micropapillary histology allowed No evidence of disease outside the pelvis PATIENT CHARACTERISTICS: Age Any age Performance status 0-2 Life expectancy Not specified Hematopoietic Bone marrow function adequate Hepatic Liver function adequate Renal Creatinine clearance ≥ 45 mL/min Cardiovascular Ejection fraction ≥ 50% Other Not pregnant No other malignancy likely to be life-threatening within the next 4 years PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy Not specified Endocrine therapy Not specified Radiotherapy Not specified Surgery See Disease Characteristics
Sites / Locations
- M.D. Anderson Cancer Center at University of Texas